Summaries of the Section H (HML) update

Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.

The table on this page gives a preview of the upcoming changes that will be announced in next month’s Section H of the Pharmaceutical Schedule.

The changes will be published in the Online HML(external link) around the 23^rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.

18 September 2023 - preview of changes for October 2023

Pharmaceutical	Change
Alprostadil inj 10 mcg vial and 20 mcg vial	new listing
Amitriptyline (Arrow-Amitriptyline) tab 10 mg, 25 mg and 50 mg	price increase and addition of PSS
Bendroflumethiazide [Bendrofluazide] (Arrow-Bendrofluazide) tab 2.5 mg and 5 mg	price increase and addition of PSS
Calamine (healthE Calamine Aqueous) crm, aqueous, BP, 100 g	new listing (p’code 2318628)
Cefalexin (Cefalexin Sandoz) grans for oral liq 50 mg per ml, 100 ml	new listing (p’code 2332825)
Cefazolin (Cefazolin-AFT)
Inj 500 mg vial	addition of PSS and amendment of brand name
Inj 1 g vial	price increase, addition of PSS and amendment of brand name
inj 2 g vial	new listing and addition of PSS (p’code 2662876)
Diazepam (Arrow-Diazepam) tab 2 mg and 5 mg	price increase and addition of PSS
Emicizumab (Hemlibra) Inj 30 mg in 0.1 ml vial Inj 60 mg in 0.4 ml vial Inj 105 mg in 0.7 ml vial Inj 150 mg in 1 ml vial	amended restriction criteria
Entecavir tab 0.5 mg	Brand change Entecavir (Rex) – new listing and addition of PSS (p’code 2654431) Entecavir Sandoz – to be delisted 1 March 2024
Latanoprost with timolol (Arrow – Lattim) eye drops 0.005% with timolol 0.5%, 2.5 ml	price increase and addition of PSS
Losartan potassium (Losartan Actavis) tab 12.5 mg, 25 mg, 50 mg and 100 mg	price increase and addition of PSS
Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride (Glycoprep-O) powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet	Glycoprep-O, 12 sachet pack - new pack size listing (p’code 2637995) Glycoprep-O, 3 sachet pack - extend PSS end date (p’code 2637987)
Mepolizumab (Nucala) inj 100 mg vial	to be delisted 1 August 2024
Metoclopramide hydrochloride (Metoclopramide Actavis 10) tab 10 mg	price increase and addition of PSS
Multiple Sclerosis Treatments dimethyl fumarate fingolimod glatiramer acetate interferon beta-1-alpha interferon beta-1-beta natalizumab teriflunomide	amended restriction criteria
Naltrexone hydrochloride (Naltrexone AOP) tab 50 mg	new listing (p’code 2664941)
Nifedipine (Tensipine MR10) tab long-acting 10 mg	price increase
Nimodipine (Nimotop) inj 200 mcg per ml, 50 ml vial	Pack size change ·5 inj pack - new listing (p’code 2663937) 1 inj pack - to be delisted 1 April 2024
Ocrelizumab (Ocrevus) inj 30 mg per ml, 10 ml vial	chemical moved to new TG3 and new restriction criteria
Omeprazole Cap 10 mg (Omeprazole actavis 10) Cap 20 mg (Omeprazole actavis 20) Cap 40 mg (Omeprazole actavis 40)	price increase and addition of PSS
Ondansetron tab dispersible 4 mg and 8 mg	Brand change Periset ODT - new listing and addition of PSS tab dispersible 4 mg (p’code 2656868) tab dispersible 8 mg (p’code 2656876) Ondansetron ODT-DRLA - to be delisted from 1 March 2024


Pertuzumab (Perjeta) inj 30 mg per ml, 14 ml vial	amended restriction criteria
Prochlorperazine (Nausafix) tab 5 mg	price increase and addition of PSS
Risperidone	price increase and addition of PSS
Tab 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg (Risperidone (Teva))
Oral liq 1 mg per ml, 30 ml (Risperon)
Simvastatin tab 10 mg, 20 mg, 40 mg and 80 mg	Simvastatin Mylan –price increase addition of PSS, and revoking delisting Simvastatin Viatris – removal of PSS
Temozolomide (Temaccord) cap 5 mg, 20 mg, 100 mg, 140 mg and 250 mg	amended restriction criteria
Timolol (Arrow-Timolol) eye drops 0.25%, 5 ml and 0.5%, 5 ml	price increase and addition of PSS
Trastuzumab (Herceptin) inj 150 mg vial and 440 mg vial	amended restriction criteria
Zidovudine [AZT] with lamivudine (Lamivudine/Zidovudine Viatris) tab 300 mg with lamivudine 150 mg	new listing (p’code 2645300)

Find previous months' summaries